Lucentis SAILOR Trial Hits Choppy Water
This article was originally published in The Pink Sheet Daily
Executive Summary
Interim analysis of neovascular AMD patients shows a higher incidence of stroke in patients treated with 0.5 mg dose of Lucentis.
You may also be interested in...
NICE Recommends Lucentis In 20 Percent Of Wet AMD Patients
Draft guidance by U.K. watchdog recommends Lucentis in certain patients with wet AMD but does not recommend Macugen.
NICE Recommends Lucentis In 20 Percent Of Wet AMD Patients
Draft guidance by U.K. watchdog recommends Lucentis in certain patients with wet AMD but does not recommend Macugen.
OSI Pharmaceuticals President Colin Goddard: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Goddard talks about OSI’s pipeline, dealing with competition from Pfizer and Genentech, and how he plans to “demonstrate a full year of profitability” in 2007.